CYABRA, INC. (CYAB) director boosts stake with stock and warrant buys
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
CYABRA, INC. director James Francis Flanagan increased his exposure on July 10, 2026. He acquired 114,940 shares of common stock at $0.435 per share in a private placement, bringing his direct common stock holdings to 224,940 shares. He also purchased two series of common stock warrants, each covering 114,940 shares, with exercise prices of $0.50 and $0.45 per share. These warrants were bought in the same private placement and will become exercisable only after requisite stockholder approval, with one series expiring 12 months and the other five years after the initial exercise date.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 229,880 shares ($109,193)
Net Buy
3 txns
Insider
Flanagan James Francis
Role
Director
Bought
229,880 shs ($109K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock Warrants (right to buy) | 114,940 | $0.45 | $52K |
| Purchase | Common Stock Warrants (right to buy) | 114,940 | $0.50 | $57K |
| Grant/Award | Common Stock | 114,940 | $0.435 | $50K |
Holdings After Transaction:
Common Stock Warrants (right to buy) — 114,940 shares (Direct);
Common Stock — 224,940 shares (Direct)
Footnotes (1)
- On July 10, 2026, the Reporting Person purchased 53,650 shares of common stock, par value $0.0001 per share (the "Common Stock"), from the Issuer in a private placement transaction (the "Private Placement") at a purchase price of $0.435 per share. The Reporting Person purchased Series B warrants to purchase up to 53,650 shares of Common Stock (the "Series B Warrants") in the Private Placement. The Series B Warrants will become exercisable upon the receipt of the requisite stockholder approval. The Series B Warrants expire twelve (12) months following the initial exercise date. The Reporting Person purchased Series A warrants to purchase up to 53,650 shares of Common Stock (the "Series A Warrants") in the Private Placement. The Series A Warrants will become exercisable upon the receipt of the requisite stockholder approval. The Series A Warrants expire five (5) years following the initial exercise date.
Key Figures
Common shares acquired: 114,940 shares
Purchase price per share: $0.435
Common shares held after transaction: 224,940 shares
+3 more
6 metrics
Common shares acquired
114,940 shares
Common stock acquired on July 10, 2026 at $0.435 per share
Purchase price per share
$0.435
Price paid for each common share in the private placement
Common shares held after transaction
224,940 shares
Director’s direct common stock holdings following the July 10, 2026 acquisition
Warrants purchased (Series with $0.50 exercise price)
114,940 warrants
Common Stock Warrants acquired July 10, 2026 with $0.50 exercise price
Warrants purchased (Series with $0.45 exercise price)
114,940 warrants
Common Stock Warrants acquired July 10, 2026 with $0.45 exercise price
Underlying common shares per warrant series
114,940 shares
Each warrant series is exercisable for 114,940 shares of common stock
Key Terms
private placement, Series A warrants, Series B warrants, requisite stockholder approval, +1 more
5 terms
private placement financial
"purchased 53,650 shares of common stock ... in a private placement transaction"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
Series A warrants financial
"purchased Series A warrants to purchase up to 53,650 shares of Common Stock"
Series A warrants are financial tools that give the holder the right to buy shares of a company at a specific price within a certain period. They are often issued alongside investments to provide additional potential profit if the company's value increases. For investors, they can offer a chance to benefit from future growth without committing immediate capital to buying shares.
Series B warrants financial
"purchased Series B warrants to purchase up to 53,650 shares of Common Stock"
Series B warrants are contracts issued alongside a company's Series B financing that give the holder the right to buy a set number of shares at a fixed price within a specified time. For investors, they matter because they can provide leveraged upside if the company grows, or they can dilute existing shareholders when exercised—like a coupon promising a future share at a known price that can add value or change ownership stakes.
requisite stockholder approval regulatory
"will become exercisable upon the receipt of the requisite stockholder approval"
initial exercise date financial
"expire twelve (12) months following the initial exercise date"
FAQ
What did CYAB (CYABRA, INC.) director James Francis Flanagan acquire on July 10, 2026?
James Francis Flanagan acquired 114,940 shares of CYABRA, INC. common stock at $0.435 per share in a private placement, increasing his direct common stock holdings to 224,940 shares as of that transaction date.
How many CYAB (CYABRA, INC.) warrants did James Francis Flanagan purchase and at what prices?
Flanagan purchased two series of common stock warrants, each for 114,940 underlying shares, with exercise prices of $0.50 and $0.45 per share, in a private placement on July 10, 2026.
When do the CYAB (CYABRA, INC.) Series A and Series B warrants held by James Francis Flanagan become exercisable?
Both the Series A and Series B warrants will become exercisable only upon receipt of the requisite stockholder approval, as described in the transaction footnotes for James Francis Flanagan.
What are the expiration terms of the CYAB (CYABRA, INC.) Series A and Series B warrants purchased by James Francis Flanagan?
The Series B warrants expire 12 months after the initial exercise date, while the Series A warrants expire five years after the initial exercise date, according to the footnotes describing these warrant purchases.
What are James Francis Flanagan’s direct common stock holdings in CYAB (CYABRA, INC.) after the reported transactions?
After acquiring 114,940 shares on July 10, 2026, Flanagan directly holds 224,940 shares of CYABRA, INC. common stock, as reported in the post-transaction ownership field of the Form 4 data.
Are James Francis Flanagan’s CYAB (CYABRA, INC.) warrant purchases open-market or private transactions?
The warrants were purchased in a private placement with CYABRA, INC., as indicated in the footnotes, even though the transaction code reflects a purchase-type transaction rather than an option exercise.